Here are the DEF 14A proxy statements from Aramark (ARMK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ARMK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARMK filings page.
Aramark outlines strong 2025 performance and key voting items in its 2026 proxy statement. The company reports three-year compound annual growth rates of 11% for revenue and 24% for profitability, nearly $1 billion in net new business (5.6% of prior-year revenue), record gross new business of $1.6 billion (12% higher than prior year), and a client retention rate of 96.3%. Cash flow from operations rose 27% and free cash flow 41%, reducing the leverage ratio to 3.25x, the lowest since before going private in 2007. Aramark highlights broad deployment of AI across food production and supply chain and several large contract wins, including its largest U.S. contract with the University of Pennsylvania Health System. Shareholders are asked to elect 11 directors, ratify Deloitte & Touche LLP for fiscal 2026, and approve executive pay, after a 2025 annual bonus payout at 133% of target and PSU vesting at 89.1% of target.